Smallpox Treatment Market Size 2025-2029
The smallpox treatment market size is forecast to increase by USD 89223.4 thousand, at a CAGR of 2.3% between 2024 and 2029.
The global smallpox treatment market is shaped by government initiatives to increase the stockpiling of therapeutics. This is a critical component of biodefense preparedness, addressing the risk of re-emergence from bioterrorism or accidental release. The primary focus is on maintaining a ready supply of both vaccines and antiviral drugs to manage a public health emergency. This strategy requires significant investment in resources, personnel, and infrastructure to support a rapid and effective response, including robust systems for contact tracing and patient isolation. The ongoing efforts in the vaccine research market aim to develop safer and more effective countermeasures.Heightened awareness of bioterrorism threats is prompting increased R&D efforts from companies, with a focus on advanced antiviral drugs and next-generation vaccines. This trend is supported by government funding and collaborations between public and private sectors, accelerating innovation in the infectious disease space. However, significant logistical complexities are involved in vaccine storage and transportation, requiring specialized equipment and trained personnel to maintain efficacy and prevent spoilage. This includes adherence to strict cold chain protocols and emergency plans.- Development of next-generation vaccines with improved safety profiles.
- Investment in advanced antiviral drugs for post-exposure treatment.
What will be the Size of the Smallpox Treatment Market during the forecast period?
Explore in-depth regional segment analysis with market size data - historical 2019 - 2023 and forecasts 2025-2029 - in the full report.
Request Free Sample
The market's primary focus is on biodefense preparedness, with activities centered around government procurement of orthopoxvirus countermeasures for strategic national stockpiles. This dynamic shapes the entire value chain, from R&D funding for non-replicating smallpox vaccines to long-term contracts for antiviral drug development. The ecosystem is characterized by close public-private partnerships, where innovation is guided by national security needs rather than commercial demand. The emphasis is on ensuring a rapid and effective public health emergency response, making supply chain security and regulatory compliance through pathways like the Animal Rule critical.Continuous innovation is essential to address evolving threats, including synthetic biology and waning vaccine-induced immunity in the global population. This drives research into next-generation vaccines with improved safety profiles and broad-spectrum antivirals effective against various orthopoxviruses. Efforts in the vaccine research market also concentrate on logistical improvements, such as freeze-dried vaccine formulation, to overcome cold chain challenges. This ongoing development ensures that the response to any future infectious disease outbreak remains effective and technologically advanced.
How is this Smallpox Treatment Industry segmented?
The smallpox treatment industry research report provides comprehensive data (region-wise segment analysis), with forecasts and estimates in "USD thousand" for the period 2025-2029, as well as historical data from 2019 - 2023 for the following segments.
- Product
- Route of administration
- End-user
- Hospitals
- Specialty clinics
- Homecare
- Geography
- North America
- Europe
- Germany
- UK
- France
- Italy
- Spain
- The Netherlands
- Asia
- Rest of World (ROW)
By Product Insights
The drugs segment is estimated to witness significant growth during the forecast period.
The drugs segment is the largest contributor to the market, driven by the critical need for effective post-exposure treatments in the event of an outbreak. Unlike vaccines, which are primarily prophylactic, antiviral drugs can be administered to symptomatic patients, making them an indispensable component of any comprehensive biodefense strategy. The development of these therapeutics, facilitated by priority reviews and specialized regulatory pathways, addresses the demand for solutions that can manage active infections and improve patient outcomes, complementing vaccine-based prevention strategies.
This segment's dominance is underscored by its significant market share, accounting for approximately 68.6% of total revenue in the previous year. The growth is supported by substantial government funding for the research, development, and procurement of novel small-molecule drugs for national stockpiles. The focus on antiviral drug development is also due to the relatively lower complexity and cost compared to vaccine manufacturing, along with a more favorable side-effect profile, which enhances potential patient adherence during a public health emergency.
Request Free Sample
The Drugs segment was valued at USD 479,717.40 None in 2019 and showed a gradual increase during the forecast period.
Regional Analysis
North America is estimated to contribute 61.2% to the growth of the global market during the forecast period.Technavio’s analysts have elaborately explained the regional trends and drivers that shape the market during the forecast period.
Request Free Sample
The market in North America is characterized by a robust and highly structured biodefense strategy, positioning the region as the global leader. This dominance is driven by substantial and consistent federal government investment in public health preparedness, primarily managed through agencies responsible for the Strategic National Stockpile. Procurement is dictated by long-term biodefense goals rather than commercial demand. These efforts ensure a ready supply of medical countermeasures, including advanced antiviral drugs and next-generation vaccines, for deployment during a public health emergency.
North America's market activity is overwhelmingly dictated by these strategic procurement contracts, with the region contributing 61.23% of the overall incremental growth. The focus is not only on stockpiling but also on funding research and development for next-generation countermeasures to address evolving threats. The established regulatory framework, including the Animal Rule pathway, facilitates the approval of necessary therapeutics, ensuring the region maintains a high state of readiness against potential biological threats and continues to shape global standards for preparedness.
Market Dynamics
Our researchers analyzed the data with 2024 as the base year, along with the key drivers, trends, and challenges. A holistic analysis of drivers will help companies refine their marketing strategies to gain a competitive advantage.
The global market is increasingly shaped by comprehensive biodefense strategies against synthetic variola virus, addressing the significant synthetic genomics and bioweapon proliferation risk. The role of public-private partnerships in preparedness is central to this effort, facilitating the strategic stockpiling of antiviral therapeutics and enabling efficient contract manufacturing for biodefense countermeasures. These collaborations are vital for accelerating the development of next-generation smallpox vaccines and the development of broad-spectrum orthopoxvirus antivirals. Navigating complex regulatory pathways for emergency drug approval is a key focus, alongside research into enhancing vaccine-induced immunity duration and advanced vaccine development for orthopoxviruses.An effective public health response to potential outbreaks depends on overcoming logistical challenges in mass vaccination campaigns and ensuring robust cold chain management for smallpox vaccines. The availability of rapid diagnostic tools for orthopoxvirus detection is critical for early containment. Clinically, priorities include post-exposure prophylaxis efficacy studies and the careful clinical management of severe smallpox cases. There is a specific focus on smallpox treatment for immunosuppressed patients and managing adverse events from smallpox vaccination. Furthermore, the industry is actively assessing waning immunity in vaccinated populations and exploring novel methods for improving patient outcomes through immunotherapy.
What are the key market drivers leading to the rise in the adoption of Smallpox Treatment Industry?
- The primary driver for the market is the increasing government-led stockpiling of smallpox therapeutics to prepare for potential outbreaks.
Increasing government-led stockpiling of smallpox therapeutics is the primary factor driving the market. With smallpox recognized as a category A bioterrorism agent, national health authorities are focusing on building and maintaining strategic reserves of vaccines and antiviral drugs as a critical biodefense preparedness measure. This response is vital, as a large portion of the global population lacks vaccine-induced immunity. The re-emergence of the virus could lead to high morbidity and mortality, with the death rate associated with smallpox historically estimated at 30%-40%. These stockpiling efforts require significant investment in healthcare system capacity, including contact tracing protocols and infrastructure for mass casualty events, to ensure a swift and effective public health emergency response.The market is also driven by the increasing approval of effective drugs, which addresses the demand for therapies that can treat the disease post-infection. The existing regimen, largely reliant on prophylactic vaccines, leaves a gap for patients who are already symptomatic. The US FDA's approval of new therapeutics under its Animal Rule pathway, which allows for efficacy data from animal models when human trials are unethical or infeasible, has been a significant development. This regulatory flexibility encourages companies to invest in research for novel antiviral drug development. These approvals provide tangible therapeutic options, enhancing epidemic preparedness and satisfying the need for effective treatments beyond prevention.
What are the market trends shaping the Smallpox Treatment Industry?
- A key market trend is the rising investment and research efforts by pharmaceutical and biotechnology companies in developing advanced smallpox countermeasures.
The market is witnessing a significant trend of increasing efforts by pharmaceutical and biotechnology companies, driven by a heightened awareness of bioterrorism threats and the need for epidemic preparedness. Despite the eradication of smallpox, the potential for its re-emergence through synthetic biology or deliberate release has prompted heavy investment in research and development. This includes the development of advanced antiviral drugs and next-generation vaccines. These innovations in the infectious disease landscape are supported by substantial government funding and public-private partnerships, which are accelerating the pace of innovation in the vaccine research market and bolstering national security.The growing threat of bioterrorism continues to be a powerful trend shaping the market, as public health authorities remain concerned about the potential misuse of the variola virus as a bioweapon. Although only two authorized labs preserve the virus, the risk of synthetic strains falling into the wrong hands persists. This concern has led to increased demand for preventive measures and countermeasures for this specific infectious disease. Since a large portion of the population has never been vaccinated, a single confirmed case would constitute a global emergency. Consequently, healthcare regulatory bodies are preparing for such events by stockpiling therapeutics, a measure that is anticipated to have a positive impact on the market.
What challenges does the Smallpox Treatment Industry face during its growth?
- A significant challenge impacting the market involves the logistical complexities associated with the stringent storage and transportation requirements for vaccines.
A significant challenge impacting the market involves the complexities of vaccine storage and transportation, which demand stringent cold chain logistics and specialized infrastructure. The transportation of vaccines requires validated protocols, adequate packaging like coolers and cold packs, and temperature-controlled storage units, which can cost thousands of dollars. Improper handling or storage at incorrect temperatures can lead to vaccine spoilage and increased risk of a disease outbreak. To mitigate these risks, facilities must employ trained vaccine coordinators to oversee inventory, monitor temperatures, and maintain detailed documentation, adding operational overhead and discouraging new entrants into the market.The adverse side-effects associated with smallpox vaccines present another key challenge, limiting their use for routine vaccination. While effective, these vaccines can cause reactions ranging from mild soreness to serious, life-threatening conditions. For instance, approximately one in every 1,000 people vaccinated for the first time experiences serious, non-life-threatening reactions requiring medical intervention. Life-threatening reactions, though rarer, can also occur, particularly in individuals with weakened immune systems or certain skin conditions. Variola major, the most common and severe form of smallpox, has a mortality rate of approximately 30%, which underscores the need for effective countermeasures, but the risk profile of current vaccines restricts their broad application, thereby impeding market growth.
Exclusive Customer Landscape
The smallpox treatment market forecasting report includes the adoption lifecycle of the market, covering from the innovator’s stage to the laggard’s stage. It focuses on adoption rates in different regions based on penetration. Furthermore, the smallpox treatment market report also includes key purchase criteria and drivers of price sensitivity to help companies evaluate and develop their market growth analysis strategies.
Customer Landscape
Key Companies & Market Insights
Companies are implementing various strategies, such as strategic alliances, smallpox treatment market forecast, partnerships, mergers and acquisitions, geographical expansion, and product/service launches, to enhance their presence in the industry.
Bavarian Nordic AS - Offerings in the market are centered on providing critical medical countermeasures for biodefense and public health emergencies. Companies focus on the development, manufacturing, and commercialization of life-saving therapeutics, including antiviral drugs designed to treat active smallpox infections and next-generation vaccines for prophylactic use. These key offerings are supplied through large-scale government contracts for national strategic stockpiles. Core activities include R&D for novel treatments with improved safety and efficacy profiles, securing regulatory approvals through specialized pathways, and ensuring supply chain readiness for rapid deployment in a crisis. The portfolio addresses public health threats with solutions designed for both military and civilian protection against orthopoxviruses.
The industry research and growth report includes detailed analyses of the competitive landscape of the market and information about key companies, including:
- Bavarian Nordic AS
- BioFactura Inc.
- Emergent BioSolutions Inc.
- EpiVax Inc.
- Inovio Pharmaceuticals Inc.
- KM Biologics Co. Ltd.
- Marker Therapeutics Inc.
- Oncovir Inc.
- Pfizer Inc.
- SIGA Technologies Inc.
- Tonix Pharmaceuticals Holding
Qualitative and quantitative analysis of companies has been conducted to help clients understand the wider business environment as well as the strengths and weaknesses of key industry players. Data is qualitatively analyzed to categorize companies as pure play, category-focused, industry-focused, and diversified; it is quantitatively analyzed to categorize companies as dominant, leading, strong, tentative, and weak.
Recent Development and News in Smallpox Treatment Market
In March 2024, Bavarian Nordic AS announced positive results from a Phase 3 clinical trial of its freeze-dried MVA-BN smallpox and mpox vaccine, demonstrating that it was non-inferior to the liquid-frozen formulation, which could improve logistical and storage requirements for national stockpiles.In February 2024, Emergent BioSolutions Inc. announced it had secured a contract modification from the US Department of Defense valued at approximately $79 million for the supply of its ACAM2000 (SMALLPOX (VACCINIA) Vaccine, Live) to support military readiness.In January 2024, SIGA Technologies Inc. was awarded a new contract from the Biomedical Advanced Research and Development Authority (BARDA) for the procurement of oral TPOXX (TECOVIRIMAT) treatment courses, with a value of approximately $138 million, to bolster the Strategic National Stockpile.
Research Analyst Overview
The global smallpox treatment market evolves around continuous biodefense preparedness for a potential mass casualty event or public health emergency. This necessitates sophisticated management of the strategic national stockpile, which includes a dynamic inventory of orthopoxvirus countermeasures. The focus of antiviral drug development and vaccine research is shifting, with public-private partnerships driving innovation beyond the traditional live-virus vaccine toward a non-replicating smallpox vaccine. A key objective is ensuring robust vaccine-induced immunity, verified through rigorous immunogenicity assessment, while accommodating individuals with immunosuppressive conditions. This ongoing development aims to mitigate the known adverse side-effect profile of older vaccines, such as post-vaccinal encephalitis and eczema vaccinatum, enhancing overall epidemic preparedness.The operational landscape is shaped by the persistent risk of a bioterrorism agent and emerging synthetic biology threats, which makes variola virus research and viral strain preservation critical activities conducted under biosafety level 4 containment. Regulatory navigation for a new countermeasure progresses from an investigational new drug to a biologics license application or emergency use authorization, often leveraging the animal rule pathway. Production integrity is maintained by contract manufacturing organizations adhering to good manufacturing practice for active pharmaceutical ingredients. Expectations for supply chain modernization anticipate an efficiency improvement of over 14%, directly impacting cold chain logistics through advanced temperature excursion monitoring and fortified vaccine storage protocols. A rapid response relies on healthcare system capacity to administer post-exposure prophylaxis, including options for intravenous drug delivery, coordinated with effective contact tracing protocols.
Dive into Technavio’s robust research methodology, blending expert interviews, extensive data synthesis, and validated models for unparalleled Smallpox Treatment Market insights. See full methodology.
|
Market Scope
|
|
Report Coverage
|
Details
|
|
Page number
|
275
|
|
Base year
|
2024
|
|
Historic period
|
2019 - 2023 |
|
Forecast period
|
2025-2029
|
|
Growth momentum & CAGR
|
Accelerating at a CAGR of 2.3%
|
|
Market growth 2024-2029
|
USD 89223.4 thousand
|
|
Market structure
|
Concentrated
|
|
YoY growth 2024-2029(%)
|
2.2%
|
|
Key countries
|
US, Canada, Mexico, Germany, UK, France, Italy, Spain, The Netherlands, China, India, Japan, South Korea, Indonesia, Thailand, Brazil, Saudi Arabia, UAE, Turkey, Argentina, Colombia, South Africa, Israel
|
|
Competitive landscape
|
Leading Companies, Market Positioning of Companies, Competitive Strategies, and Industry Risks
|
Request Free Sample
What are the Key Data Covered in this Smallpox Treatment Market Research and Growth Report?
- CAGR of the Smallpox Treatment industry during the forecast period
- Detailed information on factors that will drive the growth and forecasting between 2024 and 2029
- Precise estimation of the size of the market and its contribution of the industry in focus to the parent market
- Accurate predictions about upcoming growth and trends and changes in consumer behaviour
- Growth of the market across North America, Europe, Asia, Rest of World (ROW)
- Thorough analysis of the market’s competitive landscape and detailed information about companies
- Comprehensive analysis of factors that will challenge the smallpox treatment market growth of industry companies
We can help! Our analysts can customize this smallpox treatment market research report to meet your requirements.
Get in touch
1 Executive Summary
- 1 Executive Summary
- 1.1 Market overview
- Executive Summary - Chart on Market Overview
- Executive Summary - Data Table on Market Overview
- Executive Summary - Chart on Global Market Characteristics
- Executive Summary - Chart on Market by Geography
- Executive Summary - Chart on Market Segmentation by Product
- Executive Summary - Chart on Market Segmentation by Route of Administration
- Executive Summary - Chart on Market Segmentation by End-user
- Executive Summary - Chart on Incremental Growth
- Executive Summary - Data Table on Incremental Growth
- Executive Summary - Chart on Company Market Positioning
2 Technavio Analysis
- 2 Technavio Analysis
- 2.1 Analysis of price sensitivity, lifecycle, customer purchase basket, adoption rates, and purchase criteria
- Analysis of price sensitivity, lifecycle, customer purchase basket, adoption rates, and purchase criteria
- 2.2 Criticality of inputs and Factors of differentiation
- Chart on Overview on criticality of inputs and factors of differentiation
- 2.3 Factors of disruption
- Chart on Overview on factors of disruption
- 2.4 Impact of drivers and challenges
- Chart on Impact of drivers and challenges in 2024 and 2029
3 Market Landscape
- 3 Market Landscape
- 3.1 Market ecosystem
- Chart on Parent Market
- Data Table on - Parent Market
- 3.2 Market characteristics
- Chart on Market characteristics analysis
- 3.3 Value chain analysis
- Chart on Value chain analysis
4 Market Sizing
- 4 Market Sizing
- 4.1 Market definition
- Data Table on Offerings of companies included in the market definition
- 4.2 Market segment analysis
- 4.3 Market size 2024
- 4.4 Market outlook: Forecast for 2024-2029
- Chart on Global - Market size and forecast 2024-2029 ($ thousand)
- Data Table on Global - Market size and forecast 2024-2029 ($ thousand)
- Chart on Global Market: Year-over-year growth 2024-2029 (%)
- Data Table on Global Market: Year-over-year growth 2024-2029 (%)
5 Historic Market Size
- 5 Historic Market Size
- 5.1 Global Smallpox Treatment Market 2019 - 2023
- Historic Market Size - Data Table on Global Smallpox Treatment Market 2019 - 2023 ($ thousand)
- 5.2 Product segment analysis 2019 - 2023
- Historic Market Size - Product Segment 2019 - 2023 ($ thousand)
- 5.3 Route of Administration segment analysis 2019 - 2023
- Historic Market Size - Route of Administration Segment 2019 - 2023 ($ thousand)
- 5.4 End-user segment analysis 2019 - 2023
- Historic Market Size - End-user Segment 2019 - 2023 ($ thousand)
- 5.5 Geography segment analysis 2019 - 2023
- Historic Market Size - Geography Segment 2019 - 2023 ($ thousand)
- 5.6 Country segment analysis 2019 - 2023
- Historic Market Size - Country Segment 2019 - 2023 ($ thousand)
6 Qualitative Analysis
- 6 Qualitative Analysis
- 6.1 Impact of AI on Global Smallpox Treatment Market
7 Five Forces Analysis
- 7 Five Forces Analysis
- 7.1 Five forces summary
- Five forces analysis - Comparison between 2024 and 2029
- 7.2 Bargaining power of buyers
- Bargaining power of buyers - Impact of key factors 2024 and 2029
- 7.3 Bargaining power of suppliers
- Bargaining power of suppliers - Impact of key factors in 2024 and 2029
- 7.4 Threat of new entrants
- Threat of new entrants - Impact of key factors in 2024 and 2029
- 7.5 Threat of substitutes
- Threat of substitutes - Impact of key factors in 2024 and 2029
- 7.6 Threat of rivalry
- Threat of rivalry - Impact of key factors in 2024 and 2029
- 7.7 Market condition
- Chart on Market condition - Five forces 2024 and 2029
8 Market Segmentation by Product
- 8 Market Segmentation by Product
- 8.1 Market segments
- Chart on Product - Market share 2024-2029 (%)
- Data Table on Product - Market share 2024-2029 (%)
- 8.2 Comparison by Product
- Chart on Comparison by Product
- Data Table on Comparison by Product
- 8.3 Drugs - Market size and forecast 2024-2029
- Chart on Drugs - Market size and forecast 2024-2029 ($ thousand)
- Data Table on Drugs - Market size and forecast 2024-2029 ($ thousand)
- Chart on Drugs - Year-over-year growth 2024-2029 (%)
- Data Table on Drugs - Year-over-year growth 2024-2029 (%)
- 8.4 Vaccines - Market size and forecast 2024-2029
- Chart on Vaccines - Market size and forecast 2024-2029 ($ thousand)
- Data Table on Vaccines - Market size and forecast 2024-2029 ($ thousand)
- Chart on Vaccines - Year-over-year growth 2024-2029 (%)
- Data Table on Vaccines - Year-over-year growth 2024-2029 (%)
- 8.5 Market opportunity by Product
- Market opportunity by Product ($ thousand)
- Data Table on Market opportunity by Product ($ thousand)
9 Market Segmentation by Route of Administration
- 9 Market Segmentation by Route of Administration
- 9.1 Market segments
- Chart on Route of Administration - Market share 2024-2029 (%)
- Data Table on Route of Administration - Market share 2024-2029 (%)
- 9.2 Comparison by Route of Administration
- Chart on Comparison by Route of Administration
- Data Table on Comparison by Route of Administration
- 9.3 Intravenous - Market size and forecast 2024-2029
- Chart on Intravenous - Market size and forecast 2024-2029 ($ thousand)
- Data Table on Intravenous - Market size and forecast 2024-2029 ($ thousand)
- Chart on Intravenous - Year-over-year growth 2024-2029 (%)
- Data Table on Intravenous - Year-over-year growth 2024-2029 (%)
- 9.4 Oral - Market size and forecast 2024-2029
- Chart on Oral - Market size and forecast 2024-2029 ($ thousand)
- Data Table on Oral - Market size and forecast 2024-2029 ($ thousand)
- Chart on Oral - Year-over-year growth 2024-2029 (%)
- Data Table on Oral - Year-over-year growth 2024-2029 (%)
- 9.5 Topical - Market size and forecast 2024-2029
- Chart on Topical - Market size and forecast 2024-2029 ($ thousand)
- Data Table on Topical - Market size and forecast 2024-2029 ($ thousand)
- Chart on Topical - Year-over-year growth 2024-2029 (%)
- Data Table on Topical - Year-over-year growth 2024-2029 (%)
- 9.6 Market opportunity by Route of Administration
- Market opportunity by Route of Administration ($ thousand)
- Data Table on Market opportunity by Route of Administration ($ thousand)
10 Market Segmentation by End-user
- 10 Market Segmentation by End-user
- 10.1 Market segments
- Chart on End-user - Market share 2024-2029 (%)
- Data Table on End-user - Market share 2024-2029 (%)
- 10.2 Comparison by End-user
- Chart on Comparison by End-user
- Data Table on Comparison by End-user
- 10.3 Hospitals - Market size and forecast 2024-2029
- Chart on Hospitals - Market size and forecast 2024-2029 ($ thousand)
- Data Table on Hospitals - Market size and forecast 2024-2029 ($ thousand)
- Chart on Hospitals - Year-over-year growth 2024-2029 (%)
- Data Table on Hospitals - Year-over-year growth 2024-2029 (%)
- 10.4 Specialty clinics - Market size and forecast 2024-2029
- Chart on Specialty clinics - Market size and forecast 2024-2029 ($ thousand)
- Data Table on Specialty clinics - Market size and forecast 2024-2029 ($ thousand)
- Chart on Specialty clinics - Year-over-year growth 2024-2029 (%)
- Data Table on Specialty clinics - Year-over-year growth 2024-2029 (%)
- 10.5 Homecare - Market size and forecast 2024-2029
- Chart on Homecare - Market size and forecast 2024-2029 ($ thousand)
- Data Table on Homecare - Market size and forecast 2024-2029 ($ thousand)
- Chart on Homecare - Year-over-year growth 2024-2029 (%)
- Data Table on Homecare - Year-over-year growth 2024-2029 (%)
- 10.6 Market opportunity by End-user
- Market opportunity by End-user ($ thousand)
- Data Table on Market opportunity by End-user ($ thousand)
11 Customer Landscape
- 11 Customer Landscape
- 11.1 Customer landscape overview
- Analysis of price sensitivity, lifecycle, customer purchase basket, adoption rates, and purchase criteria
12 Geographic Landscape
- 12 Geographic Landscape
- 12.1 Geographic segmentation
- Chart on Market share by geography 2024-2029 (%)
- Data Table on Market share by geography 2024-2029 (%)
- 12.2 Geographic comparison
- Chart on Geographic comparison
- Data Table on Geographic comparison
- 12.3 North America - Market size and forecast 2024-2029
- Chart on North America - Market size and forecast 2024-2029 ($ thousand)
- Data Table on North America - Market size and forecast 2024-2029 ($ thousand)
- Chart on North America - Year-over-year growth 2024-2029 (%)
- Data Table on North America - Year-over-year growth 2024-2029 (%)
- Chart on Regional Comparison - North America
- Data Table on Regional Comparison - North America
- 12.3.1 US - Market size and forecast 2024-2029
- Chart on US - Market size and forecast 2024-2029 ($ thousand)
- Data Table on US - Market size and forecast 2024-2029 ($ thousand)
- Chart on US - Year-over-year growth 2024-2029 (%)
- Data Table on US - Year-over-year growth 2024-2029 (%)
- 12.3.2 Canada - Market size and forecast 2024-2029
- Chart on Canada - Market size and forecast 2024-2029 ($ thousand)
- Data Table on Canada - Market size and forecast 2024-2029 ($ thousand)
- Chart on Canada - Year-over-year growth 2024-2029 (%)
- Data Table on Canada - Year-over-year growth 2024-2029 (%)
- 12.3.3 Mexico - Market size and forecast 2024-2029
- Chart on Mexico - Market size and forecast 2024-2029 ($ thousand)
- Data Table on Mexico - Market size and forecast 2024-2029 ($ thousand)
- Chart on Mexico - Year-over-year growth 2024-2029 (%)
- Data Table on Mexico - Year-over-year growth 2024-2029 (%)
- 12.4 Europe - Market size and forecast 2024-2029
- Chart on Europe - Market size and forecast 2024-2029 ($ thousand)
- Data Table on Europe - Market size and forecast 2024-2029 ($ thousand)
- Chart on Europe - Year-over-year growth 2024-2029 (%)
- Data Table on Europe - Year-over-year growth 2024-2029 (%)
- Chart on Regional Comparison - Europe
- Data Table on Regional Comparison - Europe
- 12.4.1 Germany - Market size and forecast 2024-2029
- Chart on Germany - Market size and forecast 2024-2029 ($ thousand)
- Data Table on Germany - Market size and forecast 2024-2029 ($ thousand)
- Chart on Germany - Year-over-year growth 2024-2029 (%)
- Data Table on Germany - Year-over-year growth 2024-2029 (%)
- 12.4.2 UK - Market size and forecast 2024-2029
- Chart on UK - Market size and forecast 2024-2029 ($ thousand)
- Data Table on UK - Market size and forecast 2024-2029 ($ thousand)
- Chart on UK - Year-over-year growth 2024-2029 (%)
- Data Table on UK - Year-over-year growth 2024-2029 (%)
- 12.4.3 France - Market size and forecast 2024-2029
- Chart on France - Market size and forecast 2024-2029 ($ thousand)
- Data Table on France - Market size and forecast 2024-2029 ($ thousand)
- Chart on France - Year-over-year growth 2024-2029 (%)
- Data Table on France - Year-over-year growth 2024-2029 (%)
- 12.4.4 Italy - Market size and forecast 2024-2029
- Chart on Italy - Market size and forecast 2024-2029 ($ thousand)
- Data Table on Italy - Market size and forecast 2024-2029 ($ thousand)
- Chart on Italy - Year-over-year growth 2024-2029 (%)
- Data Table on Italy - Year-over-year growth 2024-2029 (%)
- 12.4.5 Spain - Market size and forecast 2024-2029
- Chart on Spain - Market size and forecast 2024-2029 ($ thousand)
- Data Table on Spain - Market size and forecast 2024-2029 ($ thousand)
- Chart on Spain - Year-over-year growth 2024-2029 (%)
- Data Table on Spain - Year-over-year growth 2024-2029 (%)
- 12.4.6 The Netherlands - Market size and forecast 2024-2029
- Chart on The Netherlands - Market size and forecast 2024-2029 ($ thousand)
- Data Table on The Netherlands - Market size and forecast 2024-2029 ($ thousand)
- Chart on The Netherlands - Year-over-year growth 2024-2029 (%)
- Data Table on The Netherlands - Year-over-year growth 2024-2029 (%)
- 12.5 Asia - Market size and forecast 2024-2029
- Chart on Asia - Market size and forecast 2024-2029 ($ thousand)
- Data Table on Asia - Market size and forecast 2024-2029 ($ thousand)
- Chart on Asia - Year-over-year growth 2024-2029 (%)
- Data Table on Asia - Year-over-year growth 2024-2029 (%)
- Chart on Regional Comparison - Asia
- Data Table on Regional Comparison - Asia
- 12.5.1 China - Market size and forecast 2024-2029
- Chart on China - Market size and forecast 2024-2029 ($ thousand)
- Data Table on China - Market size and forecast 2024-2029 ($ thousand)
- Chart on China - Year-over-year growth 2024-2029 (%)
- Data Table on China - Year-over-year growth 2024-2029 (%)
- 12.5.2 India - Market size and forecast 2024-2029
- Chart on India - Market size and forecast 2024-2029 ($ thousand)
- Data Table on India - Market size and forecast 2024-2029 ($ thousand)
- Chart on India - Year-over-year growth 2024-2029 (%)
- Data Table on India - Year-over-year growth 2024-2029 (%)
- 12.5.3 Japan - Market size and forecast 2024-2029
- Chart on Japan - Market size and forecast 2024-2029 ($ thousand)
- Data Table on Japan - Market size and forecast 2024-2029 ($ thousand)
- Chart on Japan - Year-over-year growth 2024-2029 (%)
- Data Table on Japan - Year-over-year growth 2024-2029 (%)
- 12.5.4 South Korea - Market size and forecast 2024-2029
- Chart on South Korea - Market size and forecast 2024-2029 ($ thousand)
- Data Table on South Korea - Market size and forecast 2024-2029 ($ thousand)
- Chart on South Korea - Year-over-year growth 2024-2029 (%)
- Data Table on South Korea - Year-over-year growth 2024-2029 (%)
- 12.5.5 Indonesia - Market size and forecast 2024-2029
- Chart on Indonesia - Market size and forecast 2024-2029 ($ thousand)
- Data Table on Indonesia - Market size and forecast 2024-2029 ($ thousand)
- Chart on Indonesia - Year-over-year growth 2024-2029 (%)
- Data Table on Indonesia - Year-over-year growth 2024-2029 (%)
- 12.5.6 Thailand - Market size and forecast 2024-2029
- Chart on Thailand - Market size and forecast 2024-2029 ($ thousand)
- Data Table on Thailand - Market size and forecast 2024-2029 ($ thousand)
- Chart on Thailand - Year-over-year growth 2024-2029 (%)
- Data Table on Thailand - Year-over-year growth 2024-2029 (%)
- 12.6 Rest of World (ROW) - Market size and forecast 2024-2029
- Chart on Rest of World (ROW) - Market size and forecast 2024-2029 ($ thousand)
- Data Table on Rest of World (ROW) - Market size and forecast 2024-2029 ($ thousand)
- Chart on Rest of World (ROW) - Year-over-year growth 2024-2029 (%)
- Data Table on Rest of World (ROW) - Year-over-year growth 2024-2029 (%)
- Chart on Regional Comparison - Rest of World (ROW)
- Data Table on Regional Comparison - Rest of World (ROW)
- 12.6.1 Brazil - Market size and forecast 2024-2029
- Chart on Brazil - Market size and forecast 2024-2029 ($ thousand)
- Data Table on Brazil - Market size and forecast 2024-2029 ($ thousand)
- Chart on Brazil - Year-over-year growth 2024-2029 (%)
- Data Table on Brazil - Year-over-year growth 2024-2029 (%)
- 12.6.2 Saudi Arabia - Market size and forecast 2024-2029
- Chart on Saudi Arabia - Market size and forecast 2024-2029 ($ thousand)
- Data Table on Saudi Arabia - Market size and forecast 2024-2029 ($ thousand)
- Chart on Saudi Arabia - Year-over-year growth 2024-2029 (%)
- Data Table on Saudi Arabia - Year-over-year growth 2024-2029 (%)
- 12.6.3 UAE - Market size and forecast 2024-2029
- Chart on UAE - Market size and forecast 2024-2029 ($ thousand)
- Data Table on UAE - Market size and forecast 2024-2029 ($ thousand)
- Chart on UAE - Year-over-year growth 2024-2029 (%)
- Data Table on UAE - Year-over-year growth 2024-2029 (%)
- 12.6.4 Turkey - Market size and forecast 2024-2029
- Chart on Turkey - Market size and forecast 2024-2029 ($ thousand)
- Data Table on Turkey - Market size and forecast 2024-2029 ($ thousand)
- Chart on Turkey - Year-over-year growth 2024-2029 (%)
- Data Table on Turkey - Year-over-year growth 2024-2029 (%)
- 12.6.5 Argentina - Market size and forecast 2024-2029
- Chart on Argentina - Market size and forecast 2024-2029 ($ thousand)
- Data Table on Argentina - Market size and forecast 2024-2029 ($ thousand)
- Chart on Argentina - Year-over-year growth 2024-2029 (%)
- Data Table on Argentina - Year-over-year growth 2024-2029 (%)
- 12.6.6 Colombia - Market size and forecast 2024-2029
- Chart on Colombia - Market size and forecast 2024-2029 ($ thousand)
- Data Table on Colombia - Market size and forecast 2024-2029 ($ thousand)
- Chart on Colombia - Year-over-year growth 2024-2029 (%)
- Data Table on Colombia - Year-over-year growth 2024-2029 (%)
- 12.6.7 South Africa - Market size and forecast 2024-2029
- Chart on South Africa - Market size and forecast 2024-2029 ($ thousand)
- Data Table on South Africa - Market size and forecast 2024-2029 ($ thousand)
- Chart on South Africa - Year-over-year growth 2024-2029 (%)
- Data Table on South Africa - Year-over-year growth 2024-2029 (%)
- 12.6.8 Israel - Market size and forecast 2024-2029
- Chart on Israel - Market size and forecast 2024-2029 ($ thousand)
- Data Table on Israel - Market size and forecast 2024-2029 ($ thousand)
- Chart on Israel - Year-over-year growth 2024-2029 (%)
- Data Table on Israel - Year-over-year growth 2024-2029 (%)
- 12.7 Market opportunity by geography
- Market opportunity by geography ($ thousand)
- Data Tables on Market opportunity by geography ($ thousand)
13 Drivers, Challenges, and Opportunity
- 13 Drivers, Challenges, and Opportunity
- 13.1 Market drivers
- Increasing stockpiling of smallpox therapeutics
- Increasing drug approvals
- Increasing contract manufacturing practices
- 13.2 Market challenges
- Complexities involved in vaccine storage and transportation
- Side-effects associated with smallpox vaccines
- Stringent regulatory environment
- 13.3 Impact of drivers and challenges
- Impact of drivers and challenges in 2024 and 2029
- 13.4 Market opportunities
- Increasing efforts by companies
- Growing threat of bioterrorism
- Expedited approvals
14 Competitive Landscape
- 14 Competitive Landscape
- 14.1 Overview
- 14.2 Competitive Landscape
- Overview on criticality of inputs and factors of differentiation
- 14.3 Landscape disruption
- Overview on factors of disruption
- 14.4 Industry risks
- Impact of key risks on business
15 Competitive Analysis
- 15 Competitive Analysis
- 15.1 Companies profiled
- 15.2 Company ranking index
- 15.3 Market positioning of companies
- Matrix on companies position and classification
- 15.4 Bavarian Nordic AS
- Bavarian Nordic AS - Overview
- Bavarian Nordic AS - Product / Service
- Bavarian Nordic AS - Key offerings
- SWOT
- 15.5 BioFactura Inc.
- BioFactura Inc. - Overview
- BioFactura Inc. - Product / Service
- BioFactura Inc. - Key offerings
- SWOT
- 15.6 Emergent BioSolutions Inc.
- Emergent BioSolutions Inc. - Overview
- Emergent BioSolutions Inc. - Product / Service
- Emergent BioSolutions Inc. - Key offerings
- SWOT
- 15.7 EpiVax Inc.
- EpiVax Inc. - Overview
- EpiVax Inc. - Product / Service
- EpiVax Inc. - Key offerings
- SWOT
- 15.8 Inovio Pharmaceuticals Inc.
- Inovio Pharmaceuticals Inc. - Overview
- Inovio Pharmaceuticals Inc. - Product / Service
- Inovio Pharmaceuticals Inc. - Key news
- Inovio Pharmaceuticals Inc. - Key offerings
- SWOT
- 15.9 KM Biologics Co. Ltd.
- KM Biologics Co. Ltd. - Overview
- KM Biologics Co. Ltd. - Product / Service
- KM Biologics Co. Ltd. - Key offerings
- SWOT
- 15.10 Marker Therapeutics Inc.
- Marker Therapeutics Inc. - Overview
- Marker Therapeutics Inc. - Product / Service
- Marker Therapeutics Inc. - Key offerings
- SWOT
- 15.11 Oncovir Inc.
- Oncovir Inc. - Overview
- Oncovir Inc. - Product / Service
- Oncovir Inc. - Key offerings
- SWOT
- 15.12 Pfizer Inc.
- Pfizer Inc. - Overview
- Pfizer Inc. - Product / Service
- Pfizer Inc. - Key news
- Pfizer Inc. - Key offerings
- SWOT
- 15.13 SIGA Technologies Inc.
- SIGA Technologies Inc. - Overview
- SIGA Technologies Inc. - Product / Service
- SIGA Technologies Inc. - Key offerings
- SWOT
- 15.14 Tonix Pharmaceuticals Holding
- Tonix Pharmaceuticals Holding - Overview
- Tonix Pharmaceuticals Holding - Product / Service
- Tonix Pharmaceuticals Holding - Key offerings
- SWOT
16 Appendix
- 16 Appendix
- 16.1 Scope of the report
- Market definition
- Objectives
- Notes and caveats
- 16.2 Inclusions and exclusions checklist
- Inclusions checklist
- Exclusions checklist
- 16.3 Currency conversion rates for US$
- Currency conversion rates for US$
- 16.4 Research methodology
- 16.5 Data procurement
- 16.6 Data validation
- 16.7 Validation techniques employed for market sizing
- Validation techniques employed for market sizing
- 16.8 Data synthesis
- 16.9 360 degree market analysis
- 360 degree market analysis
- 16.10 List of abbreviations
INFORMATION SOURCES
DATA ANALYSIS
REPORT WRITING
Get the report (PDF) sent to your email within minutes.
Complimentary full Excel data with your report purchase.
